SCHEMBL26656155

SCHEMBL26656155

CC(C)(C)OC(=O)C(CC1CC1(F)F)N=C(c1ccccc1)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.63
KDM4E B2RXH2 1/20 0.34
PKM P14618 1/20 0.34
MLYCD O95822 1/20 0.34
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
IDO1 P14902 1/20 0.32
SLC7A5 Q01650 1/20 0.32
ADRB2 P07550 1/20 0.32
ADRB1 P08588 1/20 0.32
ADRB3 P13945 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
CTSK P43235 1/20 0.31
CPB2 Q96IY4 2/20 0.31
ITGA4 P13612 1/20 0.31
ITGB7 P26010 1/20 0.31
PPARG P37231 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25319859 0.82 AAK1 (0.61) AAK1KDM4EPKMALDH1A1MEN1
SCHEMBL25172732 0.82 AAK1 (0.65) AAK1KDM4EPKMMLYCDALDH1A1
SCHEMBL2652864 0.81 AAK1 (0.60) AAK1KDM4EPKMALDH1A1MEN1
SCHEMBL26656125 0.81 AAK1 (0.60) AAK1KDM4EPKMMLYCDALDH1A1
SCHEMBL2652706 0.81 AAK1 (0.60) AAK1KDM4EPKMALDH1A1MEN1
SCHEMBL18782822 0.81 AAK1 (0.74) AAK1ALDH1A1TSHRHSD17B10TDP1
SCHEMBL2325860 0.79 AAK1 (0.71) AAK1ALDH1A1TSHRHSD17B10TDP1
SCHEMBL26656090 0.79 AAK1 (0.61) AAK1KDM4EPKMMLYCDALDH1A1
SCHEMBL12440732 0.78 AAK1 (0.70) AAK1ALDH1A1TSHRHSD17B10TDP1
SCHEMBL17643619 0.78 AAK1 (0.57) AAK1KDM4EPKMALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001889-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SKYHAWK THERAPEUTICS INC (US) 2026-01-01 US disclosed
EP-4522622-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2025-03-19 EP disclosed
WO-2023220439-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
WO-2023220439-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001889-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SF3B1, SF3A1, SF3B5 AAK1 3325/4885KDM4E 3466/4885PKM 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.